Recently, off-the shelf NK cell line NK-92 genetically engineered to express a HER2-targeting CAR, generating so-called NK-92/5.28.z cells have been reported to specifically lyse GBM-derived cell lines and to exhibit strong specific anti-tumor effects with prolonged survival, secondary resistance to re-challenge with tumor cells, and without relevant toxicity in xenografts and multiple immunocompetent preclinical mouse models incl. The gene discussed is ERBB2; the disease is glioblastoma.